Cancer immunotherapies have shown sustained clinical success in treating primary nonsmall-cell lung cancer (NSCLC). However, patients with brain metastasis are excluded from the trials because the brain is viewed traditionally as an immune-privileged organ. The composition and properties of tumor-infiltrating myeloid cells in metastatic brain tumors are mostly unknown. To depict the baseline landscape of the composition, gene signature, and functional states of these immune cells, we performed -single-cell RNA sequencing (scRNAseq) for 12,196cellsafter data preprocessing, including 2,241 immunecells from three surgically removed brain lesions of treatment-naïve NSCLC patients. We found a lack of T lymphocyte infiltration and activation, as well as the vast expansion of tumor-associated macrophage(TAM) in the brain lesions of NSCLC patients. By comparing our scRNAseq dataset with published data from early and late-stage primary NSCLC tumors, we showed that this compromised T cell response is unique to brain lesions. We identified a unique alternative activation (M2) gene expression pattern of the TAM in the brain metastasis and a lack of known T cell co-stimulator expression. Accumulation of M2 polarized TAM may, therefore, cause the comprised anti-tumor T cell response in metastatic brain lesions. These findings can contribute to the design of new immunotherapy strategies for NSCLC patients with brain metastasis.
Introduction
Metastatic brain tumors account for most lethality from central nervous system (CNS) malignancies in adults, which are approximately ten times frequent than a primary brain tumor 1 . The non-small cell lung cancer (NSCLC) attributes to almost half of the metastatic brain tumor diagnosed, followed by breast cancer, melanoma, renal cell carcinoma, and colorectal cancers [2] [3] [4] . Patients treated with whole-brain radiotherapy (WBRT), surgical resection, and stereotactic radiosurgery often suffer disease relapse within five years after treatment 5, 6 . Although small molecule inhibitors targeting disease-associated driver mutations such as epidermal growth factor receptor(EGFR) or anaplastic lymphoma kinase(ALK) inhibitors in NSCLC have shown efficacy in controlling intracranial disease [7] [8] [9] , most treated patients eventual developed drug resistance [10] [11] [12] . Along with a large number of patients without actionable mutations makes new therapeutic options necessary 13, 14 .
In the past five years, immune checkpoint therapies that target the T cell suppressive molecules PD-L1 and CTLA4 have significantly improved the outcomes in patients with advanced systemic disease for both NSCLC and melanoma [15] [16] [17] . In NSCLC, both nivolumab and pembrolizumab have been approved based on three significant randomized phases III studies [18] [19] [20] . A small number of patients with known active CNS disease enrolled in these trials; thus, no meaningful conclusions could be inferred regarding the impact of checkpoint blockade on the intracranial disease. Several retrospective analyses of phase II have provided the preliminary support for a possible role of checkpoint blockade in treating active brain metastases 21, 22 , and 3 clinical trials of ipilimumab in the treatment of metastatic melanoma reported an overall disease control rate (DCR) of 16% to 27% in patients with stable CNS disease 23, 24 . In a recent retrospective analysis of five patients with new or progressing brain metastases from NSCLC treated with PD-1 blockade, an objective response was observed in two patients and persisted for greater than six months, suggesting a possible role for anti-PD-1 therapy in treating CNS metastases [25] [26] [27] . While these findings are very encouraging, most PD-L1 expression positive primary NSCLC patients were failed to respond to conventional immune checkpoint therapy, let alone the ones without PD-L1 expression 28, 29 . The design of immunomodulatory strategies for the treatment of NSCLC patients with a metastatic brain tumor will tremendously benefit from a detailed understanding of the immune cell landscape that develops specifically in response to tumor cues 30 .
To shed light on the complexity of tumor-infiltrating immune cells in NSCLC with a metastatic brain tumor, we performed deep single-cell RNA sequencing on 12,196 cells, including 2,012(20.4%, 95% CI: 4.1% -36.7%) myeloid cells from 3 surgically removed brain lesions of treatment-naïve Lung adenocarcinoma (LUAD)patients. We found that lack of T cell infiltration and activation in the brain metastasis of LUAD as well as triple negative breast cancer brain metastases and glioblastoma. We identified a unique signature of the tumor-associated macrophage (TAM) in the brain metastases compared with the early and late-stage primary LUAD. We also did bulk RNA analysis on brain metastases from additional 6 LUAD patients to supplement to the limitation on low number on patient sample with single RNAseq. The low inflammatory nature of tumor cells in brain lesion and lack of T cell co-stimulator expressed on the antigen-presenting cells is one of reason underneath the lack of T cell activation.
Results
Immune landscape of brain metastasis of lung adenocarcinoma. To generate a transcriptional map of the immune cell states In human brain metastasis of lung adenocarcinoma, we constructed an atlas comprising 12,346 cells collected from freshly resected tumors of 3 treatment naïve patients (supplemental table 1). A total of 23,467 cells were subjected to single-cell RNA sequencing (scRNAseq) using the 10X genomics inDrop platform, with an average depth of 7,778 unique molecular identifiers (UMI) counts per cell(Supplemental fig.1 ).
Using tSNE to visualize high-dimensional data in two dimensions while preserving singlecell resolution 31 , we analyzed the distribution of the different stromal cell lineages that accumulated in metastatic lesions. These identified cell clusters that, through marker genes, could be readily assigned to known cell lineages: in addition to cancer cells, we identified immune cells (myeloid, T, and B cells), oligodendrocytes, endothelial cells, and pericytes ( Figure 1A,B ).
We first verified that major immune cell types were identifiable in each patient using canonical markers (Methods). The tumor-resident immune cell compartment comprised mostly of mononuclear phagocytes, including microglia (AIF, APOE, SPP1, TREM2, CSF1R, C1QA) (Gosselin et al. Science.2017) and monocyte derived macrophage (CD14, CD74,CD68, HLA-DR) ( Figure 1D ,E). In contrast, T and B lymphocytes only account for10.3%(95% CI: 6.9% -13.7%) of the total immune cell population. Strikingly, the other major myeloid population: dendritic cells, neutrophils, and NK cells, are absent in the metastatic brain lesion (Figures 1B) .
To validate our single RNAseq with brain lesions of LUAD patients, we did bulk RNA sequence on frozen human autoptic tissue specimens of brain metastases from 6 more LUAD and analysis their immune composition using CIBERSORT software 32 . Consistent with our finding with scRNAseq, the absence or low presentation of neutrophil and expansion of mononuclear phagocytes in brain lesion is confirmed (supplemental fig.2A ).However, there are more predicted T/B/NK cell population than we found in scRNAseq samples, which could reflect the tumor microenvironment variability across patients or lack the accuracy of CIBERSORT in predicting certain types of immune cells in complex tissue 33 . Conclusion:We found a lack of T and B lymphocyte infiltration, as well as the vast expansion of tumor-associated macrophage(TAM) in the brain lesions of LUAD patients.
Immune microenvironment of the brain metastasis is unique compare to primary tumor Lack of T lymphocyte infiltration and vast expansion of tumor-associated macrophage (TAM) in the brain lesions of LUAD patients is a striking contrast to related abundant of lymphocyte infiltration in primary NSCLC patients as shown in previous studies 34 . We validated these findings by histology analysis of T cell (CD3+), B cell(CD20+), and macrophage(CD68+) in both primary and brain metastatic lesions of LUAD patients (supplemental fig.3 ). We analyzed 19 human tissue specimens of brain lesions from Lung adenocarcinomapatientsand a tissue array contains 52 primary NSCLS samples (supplemental table1). Profound microglia/macrophage activation with marked peritumoral accumulation and some intra-tumoral infiltration of CD68-positive microglia/macrophages was found as previously described 35, 36 . Only a few B-and Tlymphocytes were observed in and around BM,with tertiary lymphoidstructures (TLS) (supplement fig.3 ), consistent with our findings by single cell RNAseq.
The stromal cells in tumor microenvironment has known to regulate the T cell response in various tumor 37 , we first ask whether lack of T cell infiltration in brain metastases in LUAD patients is due to its unique stromal cell status.To gain insight into the molecular signature of the tumor stromal cells across multiple stages of LUAD progression, wereanalyzed published scRNA seq data sets from early-stage LUAD 38 and late-stage LUAD 39 , along with our brain metastatic lesions (Method). Single-cell profiles of non-malignant cells highlighted the composition of the tumor microenvironment. We normalized and analyzed the distribution of non-malignant cell lineages that accumulated in early-stage, late-stage primary, and brain metastatic LUAD across patients. We annotated clusters by the expression of known marker genes as T cells, B cells, plasma cells, NK cells, macrophages, dendritic cells, mast cells, endothelial cells, pericytes, and oligodendrocyte, astrocytes. Consistent with previous findings, we also found T and B lymphocytes were present at a higher frequency in the tumor microenvironment in both early (55.8%), and late-stage LUAD (83.2%) compared to brain metastasis (10.3%)( Figure  2A ,D).In contrast, the proportion of mononuclear phagocytes was not changed much between primary lung tumor and metastatic brain lesions of LUAD patients (Figure 2A ,D). The marked transcriptional change was observed in majority of the stromal cell types based on their stage and tumor sites, visualized by distinct separation of plots in tSNE ( Figure 2B ,C). The stromal cells from metastatic brain lesions of LUAD are unique by their gene expression profiles, visualized by distinct spatial separation of early-stage, late-stage, and brain metastatic stromal cells in the principal component analysis ( Figure  2C ).
Myeloid cells have a unique ability to control T cell function at the tumor site, through their ability to present tumor-associated antigens to T cells and to produce critical T celldifferentiation cytokines [40] [41] [42] .Since the number of macrophage did not change across LUAD at different stages, we asked whether the molecular composition in primary tumor could be different from that in metastatic brain tumor.First, by mean of gene expression, the tumor specific macrophage clusters in primary tumor and brain lesion were not different a lot ( Figure 2B ). We found that beyond mean expression levels, covariance parameters varied significantly between these macrophage cluster ( Figure  3A ). This occurs due to the genes typically being co-expressed in the same cells in one cluster (positive covariance) but expressed in a mutually exclusive manner in the other cluster (negative covariance) 43 .
We also found distinct pathway expression levels of tumor-associated macrophage in brain metastasis vs. early and late-stage LUAD ( Figure 3B ), we noticed a strong enrichment of peptide antigen assembly with MHC protein complex in the metastatic brain lesion ( Figure 3B bottom panel). We noticed a substantial increase of inflammatory with neutrophil mediated immunity in late stage LUAD ( Figure 3B Furthermore, expression of genes associated with ''alternatively activated'' (M2) macrophages, including scavenger receptor CD163, Mannose Receptor MRC1, and inhibitory molecule B7-H3 (CD276) 44 , increased in brain metastatic lesion ( Figure 3C ). Concomitantly, immunostimulatory genes associated with ''classically activated'' (M1) macrophages, including chemokine CCL3/CCL4 (MIP-1a), also increased in brain metastatic lesion ( Figure 3A, supplemental fig.2B ). Among all TAM populations, particularly TAM clusters in brain lesion (cluster 4), were among the monocytic clusters with the highest expression of the canonical M2 signature but were likewise high in the M1 signature ( Figure 3C ). Quite strikingly, we found that M1 and M2 gene signatures positively correlated in the TAM populations in early stage LUAD (cluster1) and brain metastatic lesion (R=0.36 and R=0.26 respectively), but TAM in late stage lung tumor (cluster 2) more towards to M1 polarization instead (R=0.03) ( Figure 3C ), in line with recent findings in other tumor types 45 .
Conclusion: The stromal cells,largelymacrophage,in brain metastases are molecularly distinct from their counterpart in both early and late stage primary LUAD.
Paired immune cell mapping reveals a distinct macrophage signature in brain metastases of Lung Adenocarcinoma
To fully capture the heterogeneity of the TAM compartment, we first performed an unbiased single-cell transcriptomic analysis of myeloid cells that accumulated in earlystage, late-stage primary tumors and brain lesions (method). This analysis revealed seven myeloid cell clusters distinguished based on characteristic gene expression profiles identified according to highly expressed and differential genes ( Figure 4A ). Specifically, we identified a dendritic cell (DC) cluster expressing high levels of MHC class II molecules, CD1C, FCER1A, CLEC4A, and CD207 ( Figure 3B , clusters 10), which is found in primary lung tumor but absent in metastatic brain lesion. Other clusters (3, 5, 9, 16, 19, 20) were identified as macrophages ( Figure 4A ,B) based on the differential expression of CD68, CD163, and CSF1R ( Figure 4B ). Despite this diverseness, tSNE plots showed rather poor separation of clusters, suggesting that they represent diverse cell states on a graded scale rather than separate entities, in line with the spectrum model of macrophage activity 46 . Strikingly, tSNE plotting revealed a dichotomy between earlystage, late-stage primary tumor or brain lesion derived macrophages ( Figure 4C ). With 2,012myeloid cells detected after data processing, microglia/macrophage represents the most prevalent stromal cell type in metastatic brain lesions. The tissueresident macrophage population was identified as distinct cluster 3, which composed macrophages from primary lung tumor and metastatic brain lesions, with distinct gene expression AIF1, APOE, TREM2, SPP1, CD68, CD63( Figure 4B ). Enrichment of AIF1, APOE, TREM2 has been shown as the unique feature of microglia 47 , the tissue-resident macrophage in the brain, which is also highly expressed in residual macrophage,e.g.,Langerhans cells in the lung 39 .One macrophage cluster comprised predominantly of cells from metastatic brain lesions (cluster 20) were distinct from those comprised predominantly of cells from early-stage tumor lesion (cluster 9) and late-stage tumor lesion (clusters 5). This resultindicates that tumor-associated macrophages in brain lesions were distinct from their primary tumor and tissue-resident macrophage counterparts.
The early stage lung tumor-associated macrophages up-regulated the pro-inflammatory S100 calcium-binding protein A8/A9 (S100A8/A9), IFITM2, IL1B, and NFKBIA ( Figure 4B ). A similar pro-inflammatory profile was found in TAM in late-stage lung tumor lesion, with additional up-regulation of CCL2 and VEGFA. In contrast to the primary tumor, the macrophage in brain lesions shows a more antigen-presenting profile with the upregulation of various MHC II molecules (HLA-DRA, HLA-DQA, HLA-DPB) and also a component of the complement (C1QA, C1QB). This likely reflects differentiation and activation of either recruited or tissue-resident macrophages.
When different pathway expression levels of tumor-associated macrophage in brain metastasis vs. early and late-stage LUAD (supplemental fig.4 ), we noticed a strong enrichment of peptide antigen assembly with MHC protein complex across the evolution of the tumor. In early-stage LUAD, the positive regulation of regulatory T cell differentiation and Fc receptor-mediated inhibitory signaling pathway are enriched(supplemental fig.4A ), indicating T regulatory cell may play a role in tumor immune-editing at an early stage consistent with the finding previously 38 .In the late stage, LUAD, neutrophil aggregation, and production of immune inhibitory cytokines are more prominent, such as IL10 and transforming growth factor beta1 production(supplemental fig.4B ). In contrast, in the metastatic brain lesion, complement-mediated synapse pruning, positive regulation of microglial cell activation, and neutrophil clearance, indicating a brain-specific anti-inflammatory response to the tumor(supplemental fig.4C ).
Conclusion:Detailed analysis of the macrophage activation in the brain lesion of LUAD patient versus its primary tumor counterpart reveals its unique polarization states. The antigen presentation process is not disrupted in macrophage in brain lesion.
Molecular profile of the macrophage in a different stage of lung adenocarcinoma reveals brain-specific TAM lack of conventional T cell co-stimulatory Since the antigen presentation process is not disrupted in brain metastases of LUAD patients, we went on to test whether tumor cell intrinsic factors are part of the cause of lack of T cell in brain lesions. We analyzed bulk RNA sequencing data from 14 early stage and 11 late stage primary LUAD tumor from TCGA database (supplemental table 1), and alsobrain metastasis lesion from additional six treatment naïve patients. An unsupervised cluster of genes that overexpressed in tumor cells of metastatic brain lesions are distinct from the primary tumor(supplemental fig.5A ). However, PCA analysis showed the early stage (elc) and late-stage LUAD (llc) tumor cell gene expression is more closeto each other than brain metastases(supplemental fig.5B ). When contrasting pathway expression levels in brain metastasis vs. early and late-stage LUAD, we noticed a substan al reduc on of I−kappaB kinase/NF−kappaB signaling, interleukin−1−mediated signaling pathway and an gen processing and presenta on of peptide antigen via MHC class I in brain metastases (supplemental fig.5C ). In contrast, purine ribonucleotide synthesis, oxidative phosphorylationand regulation of metallopeptidase activity are up-regulated in metastatic brain lesions(supplemental fig.5D ). These data support low inflamed features of tumor cells in metastatic brain lesions but not in primary tumors.
The fact that tumor-associated macrophage composed most of the myeloid-derived suppressive cell population, it is much likely that lack of lymphocyte infiltration in metastatic brain lesion may attribute to the unique immune-suppressive feature or lack of immune co-stimulatory factors in myeloid cells in brain lesions in comparing to primary tumors.
To fully capture the immune-modulatory feature of the TAM compartment, we performed an unsupervised cluster of different gene expression of known immunestimulatory vs. inhibitory molecules in myeloid cells that accumulated inearly-stage, late-stage primary tumor and brain lesion of LUAD patient (supplemental table 2). The expression of ligands for immune checkpoint molecules, including approved targets CD274(PD-L1) and CD80 (ligand of CTLA4), but also others currently targeted in clinical trials ICOSLG (ICOS/CD278), TNFRSF9(4-1BB/CD137), CD70/TNFSF7(CD27), HLD-DRAs (LAG3), TIGIT (CD155), LGALS9 (HAVCR2/TIM3) among others are drastically different between lung tumors at different stages(Figure4D). Both T cell stimulatory and inhibitory factors are highly expressed in late-stage lung tumors, which is consistent with the abundance of cytotoxic and exhausted T cells in this tumor 48 . However, macrophage in both early-stage lung cancer and brain lesions are lack of ligands for T cell stimulatory and conventional inhibitory factors (CD274, CD86)(Figure4D). This is consistent with the lack of exhausted T cells in both early-stage lung tumors and metastatic brain lesions. 38 , the brain metastatic lesion overexpression unique set of T cell inhibitory factors including CD276/B7-H3, VTCN1 (ligand for CD272/BTLA), VEGF, IL6, which is expressed in primary lung tumors. CB7-H3, VTCN1, VEGF are also highly expressed in macrophage from breast cancer brain metastatic lesion but interestingly is absent from advanced glioblastoma(Figure4D,E).
Instead of enrichment of T regulatory cells in early lung tumors
Conclusion: These results confirmed the non-inflamed (cold) feature of brain lesion of lung adenocarcinoma. The macrophage in their microenvironment also lack expressionofT cell co-stimulatory factors.
Unique immune cell profile in brain metastasis comparing with glioblastoma
We found both metastatic brain lesions from lung and breast cancer brain metastasis sharing the expression of T cell inhibitory factors but not the glioblastoma. Comparing the cellular and molecular profiling of metastatic brain lesion (lung and Breast) with the primary tumor of brain (glioblastoma) provide a great opportunity to understand to what extent the tumor microenvironment is shaped by the tumor of the origin or the location of the tumor.
To compare the molecular signature of tumor stromal cells from brain metastases of lung adenocarcinoma and breast cancer with that of glioblastoma, we analyzed6,000 cells from freshly resected tumors from brain lesions of treatment naïve triple-negative breast cancer patient. We re-analyzed published scRNA seq data sets from 38 advanced glioblastoma patients 49 . We normalized and analyzed the distribution of non-malignant cell lineages that accumulated in these three types of brain tumors. We annotated clusters by the expression of known marker genes as T cells, plasma cells, NK cells, macrophages, dendritic cells, mast cells, endothelial cells, pericytes,oligodendrocyte and astrocytes( Figure 5A ).
Consistent with previous findings and in line with our findings in LUAD brain metastasis, we also found T and B lymphocytes were almost absent in the breast cancer brain Mets and utterly absent in glioblastoma. The mononuclear phagocytes wereabundant and account for majority of stromal cells in all three types of brain tumors. The marked transcriptional difference was observed in the majority of the stromal cell types based on their tumor of origin, visualized by distinct separation of plots in tSNE ( Figure 5B,C) . The stromal cells from metastatic brain lesions of LUAD and breast cancer are clustered together, separate from the counterpart from glioblastoma by principal component analysis ( Figure 5B,C) . Macrophages from metastatic brain lesions of LUAD and breast cancer are transcriptionally moreclose to each other than glioblastoma despite their different tumor of origin. These data indicatetumor cells that metastasize to the brain from peripheral organs elicit a different but similar innate immune response compared with tumor origin from the brain, e.g.,glioblastoma. These data emphasize the impact of tumor of origin in shaping the tumor immune response rather than the local microenvironment.Strikingly, the non-macrophage compartment of the stromal cells (endothelia, pericyte, astrocyte, oligodendrocyte) are mostly separate from each other of these three tumor types, further supporting the dominant role of cancer cell-intrinsic mechanisms in shaping the tumor microenvironment 50 .
Conclusion:When comparing with the tumor arising from brain, e.g., glioblastoma, molecular signature of stromal cells derive from lung and breast brain metastases are very distinct from their counterpart in glioblastoma. The tumor immune microenvironment of brain metastases is shaped by tumor intrinsic property that being inherent of their organ of origin (Lung and breast).
Clonal expansion of B and T cells in brain metastases of LUAD patients.
T and B cell receptor (TCR and BCR, respectively) Vβ or immunoglobulin heavy chain complementarity-determining region three sequencing allows monitoring of repertoire changes through recognition, clonal expansion, affinity maturation, and T or B cell activation in response to antigen 51 . Although the number of B and T cell are relatively lower in metastatic brain lesion of LUAD, the B cell appear to be mature plasma that high express immunoglobulin G and T cells are mostly composed of cytotoxic T cells ( Figure 1D,E) . Importantly, many patients include the three patients we had performed scRNA seq, had tertiary lymphoidstructures (TLS), which accumulated near the invasive tumormargin or within the tumor mass that was absent from healthy lung (supplemental fig.2C ).
To get insight into the clonal expansion of T cell and B cell in brain lesion of LUAD patients, V(D)J rearrangements within the BCR/ TCRβ locus are PCR-amplified with Vand J-gene specific primers and the sequence of the CDR3 was determined using highthroughput sequencing of genomic DNA isolated from 3 patients with single-cell RNAseq data available. The abundance of individual T/B cell clonotypes is determined by combining templates from molecules with the same TCRB/BCR V-gene family ( Figure  6A,B; supplemental fig.6A,B ), J-gene segment( Figure 6A; supplemental fig.6A ), and in-frameCDR3 amino acid sequence ( Figure 6D; supplemental fig.6A,C) . Among the brain lesions from three patients, atotal of 3,632,708 templates across 47,702 unique clonotypes were detected, with individual abundances ranging from 8,919 to 118,546 templates per clonotype(supplemental table3).
In both CD3+ TCR and CD20+ BCR repertoires, the clonality (average 0.57 for BCR and 0.43 for TCR) in brain lesion of LUAD patients was generally higher than that observed in the primary tumor of a cohort of 35 NSCLC patients(average 0.07 for BCR and 0.3 for TCR)and also that of 35 standard healthy donor blood specimens (average 0.06 for BCR and 0.29 for TCR )(supplemental table 3) 51 . The heterogeneity of BCR genes across three patients also showed by the clustering of V or J gene usage ( Figure 6A, B ),diverse frequency of V genes ( Figure 6B ) or VDJ rearrangement ( Figure 6C ). Three hundred BCR and 321 TCRβ clonotypes are present with an abundance higher than 0.1% in brain lesions (supplemental table 3) . Strikingly, in one patient, one clonotype with BCR CDR3 sequence "CARDYYGSGNYFPRGTLPGRVDYW" accounts for 25.5% of the total clonotypes ( Figure 6D ). On the other hand, the TCRβ with CDR3 sequence" CASSFVTGGRTEAF" accounts for 17.2% of total TCRclonotypes in one patient (supplemental fig.6D, middle panel) . This particular CDR3 sequence and also a lot of other high abundant CDR3 sequences share common motifs with a variety of virus reacting TCRs, including Cytomegalovirus (CMV), HIV-1, influenza (data not shown). The expansion of some of T cell clones are possibly not targeting the tumor-specific antigen but instead virus 52 , since the CD39 expression is also absent in majority of the T cells found in brain lesions (supplemental fig.2 ).
Conclusion: Despite the low number of T and B cells in brain metastases of LUAD patients, clonal expansion of T and B cells are apparent across the same three patients
we already performed single cell RNAseq.
Discussion
Brain metastases represent an unmet medical need in current oncologic care. Given the poor prognosis of patients with brain metastases, particularly in lung adenocarcinoma patients, there is critical need to improve our understanding of the mechanisms underlying the pathogenesis as well as to identify novel targets for immune therapies [53] [54] [55] . Advances in singlecell RNA sequencing (scRNA-seq) have allowed for a comprehensive analysis of intra-tumoral heterogeneity and tumor immune microenvironment in various cancer types at primary sites 38, 39, 43, 49, [56] [57] [58] . But not much have been done on metastatic lesions, particularly brain metastases of different cancer types. Brain has been viewed as an immune-privileged organ, but accumulating evidences start to reveal the unique feature of brain immune microenvironment in obesity, neural degenerative disease and multiple sclerosis 59, 60 . In order to understand the tumor immune microenvironment in brain lesion, we performed scRNA-seq on surgically resected brain lesionfrom three treatment-naïve LUAD patients and one triple negative breast cancer patient. We identified and profiling the different stromal cell lineages that accumulated in metastatic lesions, including immune cells (myeloid, T, and B cells), oligodendrocytes, endothelial cells, and pericytes. The expansion of macrophage and limited T and B cell infiltration is a common feature of these brain lesions. By comparing our scRNAseq data with published datasets derived from early and late-stage primary LUAD tumors 38, 39 , we found that this compromised T cell response is unique to brain lesions, while the related abundant of T lymphocyte infiltration was found in primary LUAD patients. We also found the tumor immune microenvironment of brain metastases is shaped both by tumor intrinsic property that being inherent of their organ of origin (Lung and breast) and the stromal environment of their metastatic site (brain). First, when comparing with the tumor arising from brain, e.g., glioblastoma, molecular signature of stromal cell derive from lung and breast brain metastases are very distinct from their counterpart in glioblastoma ( Figure 5B,C) . This data indicates the tumor of origin play a significant role in determining their tumor microenvironment. On the other hand, when comparing with primary lung cancer (both early and later stage), the molecular signature of stromal cell in brain lesion of LUAD patients are well separated from their counterpart in primary lung tumor. This data indicates the strong influence of metastatic sites in shaping the tumor microenvironment. Based on these findings, we defined the unique molecular signature of stromal cells within brain lesions are likely attributed to the origin of tumor cells as well as its metastatic location.
Pro-inflammatory macrophage expansion and T cell dysfunction are two known microenvironment factor that contribute to immune escape 41, 61, 62 . Macrophages formerly act as scavengers to maintain tissue homeostasis. Mounting data suggest macrophages are abundant in the tumor microenvironment of brain tumors, when educated by cancer cells, they polarized to function as immune suppress cells [63] [64] [65] [66] [67] . We performed unbiased single-cell transcriptomic analysis of myeloid cells to demonstrate that TAM in the brain metastasis has a unique alternative activation M2 signature and a lack of conventional T cell co-stimulatory factors. In addition, brain metastases associated macrophages also express unique sets of immunosuppressiveligands(CD276 and VTCN1) comparing with their primary tumor counterpart (PDL1, CD80, LILRB2/5). Despite the low number of T and B cells in brain metastases of both lung and breast cancer, abundant TCR and BCR repertoire were identified in the same three patients we already performed single cell RNAseq. The clonal expansion of T and B cells are apparent across these patients. Although Chongsathidkiet et al. proposed sequestration of T cells in bone marrow as a tumor-adaptive mode of lack of T cell in brain tumor 68 , it is still unclear to what extent this could apply for the brain metastases of lung and breast tumor 37, 69 . Since we found the TAM in brain lesion express high level of T cell chemoattractant such as CCL3 and CCL4 (supplemental fig.2B ) 70 , so it is unlikely the lack of T cells is due to the limited T cell trafficking. The general immune suppressive environment of the brain may contribute partly to the lack of T/B cells in the three type of brain tumor we examined 63 . By profiling the known immune co-stimulatory factors in TAM in brain metastases, we find lack of expression of conventional co-stimulatory factors such as PVR, TNFSF9, ICOSLG, CD40LG 71 .
In summary, we constructed the first tumor microenvironment landscape of brain metastases of LUAD patients and triple negative breast cancer by massive parallel single cell RNA sequencing. We revealed the unique transcriptomic feature of tumor stromal cells that distinct them from their counterpart in primary tumor. Expansion of immune suppressive macrophage and lack of T cell activation and expansion may explain the immune escape of the brain metastases. Our study also identified some potential targets for checkpoint inhibitors that could be further developed as novel immunotherapy that target brain metastases. Further investigation about detail mechanisms how disseminated tumor cells interact with stromal cells in brain to shape their tumor microenvironment will significantly strengthen our understanding the pathogenesis of brain metastases. Comprehensive understanding of the composition and evolution of immune microenvironment of brain metastases will guide the design of new therapeutic strategies to target these deadly diseases 30 . (D) Heatmap showing expression of distinct T cell co-stimulatory and co-inhibitory ligands on macrophages from brain metastases of LUAD (lbm) versus primary lung cancers (elc, llc) (left), and also from brain lesions from LUAD (lbm), breast cancer brain metastases (TNBC) and glioma (right). The pie graph shows the frequency of representative VDJ combinations that account for more than 1% of the total.(D)Analysis of BCR clone diversity based on specific CDR3 sequence variety. The number of specific CDR3 sequences were counted in threedifferent patients (top panel). The pie graph shows the frequency of specific CDR3 sequences that account for more than 1% of the total.
Method Human Specimens
Tumor tissues were obtained from patients undergoing brain resection surgery at the Tangdu Hospital of Fourth Military Medical University (Xi'an, China) after obtaining informed consent. All protocols were reviewed and approved by the Institutional Review Board (IRB) at the Tangdu Hospital (TDLL-201709-20).
Patient Clinical Characteristics
Samples were collected from 19 patients who were diagnosed with lung cancer and brain lesions were confirmed as lung adenocarcinoma (LUAD) subtype and 1 triple negative breast cancer (TNBC) patients with brain metastasis( Supplemental table 1 ). The 19 LUAD patients consisted of 11 males and 8 females and ranged from age 28 to 72 years old, with a median of 52 years old. The TNBC patient 44 was years old.
Sample Collection and digestion for single cell RNAseq
From the 3 of the LUAD patients and 1 TNBC patient described above, brain tissue containing the metastatic lesions was collected under surgeries at Tangdu Hospital with informed consent under a protocol approved by Fourth Military Medical University Institutional Review Board. Tissue samples were placed in DMEM/RPMI media (Corning) on ice. Small chunk of the tissue was processed for immunohistochemistry analysis by quick frozen section. H&E slides were reviewed by a pathologist and confirmed as LUAD brain metastasis or TNBC brain metastasis. The remaining freshly dissected brain tissue was cut up and then enzymatically dissociated to obtain a suspension of cells using a Tumor Dissociation Kit (MiltenyiBiotec#130-095-929) by incubating at 37 ℃ for 15 minutes. Dissociated single cells were pelleted by centrifuged at 130g for 10 minutes after removing unlysed tissue fragments with a 20μm cell strainer. The cell pellet was then resuspended in Dulbecco's phosphate-buffered saline (DPBS) containing 0.02% BSA. Cell health was assessed by trypan blue exclusion. Ensure that no less than 90% of the cell samples are alive for subsequent single-cell RNAseq (10X Genomics).
Single cell capture, library preparation, and sequencing
Single-cell libraries were prepared using the Chromium 3′ v2 platform (10X Genomics) following the manufacturer's protocol [1] by Capital Bio Technology Corporation and Novogene. Briefly, single cells were partitioned into Gel beads in Emulsion in the 10X Chromium Controller instrument followed by cell lysis and barcoded reverse transcription of RNA, amplification, shearing and 5′ adapter and sample index attachment. On average, ~10,000 cells were loaded on each channel that resulted in the recovery of ~7822 cells. Libraries were sequenced on Illumina HiSeq2500 instruments using paired-end sequencing (PE1 54 bp and PE2 66 bp). Each replicate was sequenced on one half of a HiSeq lane, at an initial depth of approximately 100 million reads.
Alignment, barcode assignment and UMI counting
The Cell Ranger Single-Cell Software Suite was used to perform sample demultiplexing, barcode processing and single-cell 3′ gene counting. First, sample demultiplexing was performed based on the 8 bp sample index read to generate FASTQs for the Read1 and Read2 paired-end reads, as well as the 14 bp GemCode barcode. Then, Read1, which contains the cDNA insert, was aligned to an appropriate reference genome using STAR. Next, GemCode barcodes and UMIs were filtered. All of the known listed of barcodes that are 1-Hamming-distance away from an observed barcode are considered. Cell barcodes were determined based on distribution of UMI counts. Number of reads that provide meaningful information is calculated as the product of four metrics: (1) valid barcodes; (2) valid UMI; (3) associated with a cell barcode; and (4) confidently mapped to exons. Samples processed from multiple channels can be combined by concatenating gene-cell-barcode matrices. In addition, sequencing data can be subsampled to obtain a given number of UMI counts per cell. For 3 LUAD patients, on average, 7,822 cells were sequenced for each patient, with 135,464 reads per cell and 2,532 genes per cells. For the one triple negative breast cancer patient, 6000 cells were sequenced, with 124,080 reads per cell and 575 genes per cells. Detailed parameter of sequencing quality are shown in Supplemental Figure 1 .
Single cell RNAseq data preprocessing
Gene expression datasets were processed with the R package of Seurat version 2. Cells were retained for downstream analysis based on the following quality measures: number of genes detected greater than 500, percentage of mitochondrial transcripts less than 5%. Raw UMI counts were normalized by dividing the number of UMIs of each gene by all UMIs of a given cell and then multiplied by 10,000. After normalization, confounding factors including the number of detected genes and proportions of mitochondrial transcripts were also regressed out. Highly variable genes used for canonical correlation analysis (CCA)with multiple groups must be highly variable in at least two datasets and having dispersion higher than 0.5 and normalized expression level between 0.0125 and 3. The top 10 PCs established with principal component analysis (PCA) were used to do clustering using Seurat. Cluster identities were assigned based on cluster gene markers as determined by FindAllMarkers function in Seuratand gene expression of known marker genes. Cluster markers were determined using Wilcoxon test as genes showing a minimum log fold expression change of 0.25 in at least a fraction of 25% of cells in the clusters. Cells were typed by examining expression of known marker genes. In this analysis, cells were scored as detecting a marker gene if the cell contained a non-zero molecule count for that gene. Each cell was corrected for its detection rate (the fraction of total genes detected in that cell) and the marker detection rate was then averaged across cells of a cluster. Markers used to type cells included NCAM1, NCR1, NKG2 (NK-cells), GNLY, GZMA, GZMB, GMZM (cytotoxic T, NK), FOXP3(T-regulatory Cell), CTLA4, TIGIT, TNFRSF4, LAG3, PDCD1 (Exhausted T-cell) , CD8, CD3, CD4 (T-cells), IL7R (Naive T-cells), CD19 (Bcells), CD79A, IGHG1, IGHA1, IGHM, JCHAIN, MZB1 (Plasma),ENPP3, KIT (Mast cells), IL3RA, LILRA4 (plasmacytoid DC), HLA-DR, FCGR3A, SPP1, AIF1, APOE, CD68, CD63, TREM2, CD14, ITGAM, (Monocytic Lineage),PECAM1, CLDN5, VWF, ESAM (Endothelia),
Supplemental table description:
Table S1. Detail clinical information of 19 Lung adenocarcinoma (LUAD) patients with brain metastases and 1 triple negative breast cancer patient with brain metastases. Also the 32 primary LUAD patients from lung tissue microarray purchased from Alenobio (Cat#LC10013b) and primary LUAD patients from TCGA database. Table S2 . List of known T cell regulatory ligands and their receptors used to make Figure  4D , E. Table S3 . Detailed sequences information for TCR and BCR VDJ rearrangement and CDR3 variety of three patients and T/B cell clonality index in 19 primary LUAD patient [11] and brain metastases of 3 LUAD patients.
